CNMD Earning Date, Earning Analysis and Earning Prediction
The article provides an earnings analysis and prediction for CNMD, including past quarterly results and future forecasts. It highlights analyst estimates for 2026/Q1, noting unchanged revenue and EPS estimates despite a recent stock price decline, suggesting potential buying opportunities. The analysis also covers historical stock price reactions around earnings announcements and addresses frequently asked questions about CNMD's financial performance and future outlook.
CNMD SEC Filings - Conmed Corp 10-K, 10-Q, 8-K Forms
This page provides access to CONMED Corporation's (NYSE: CNMD) U.S. Securities and Exchange Commission filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It offers AI-powered tools to interpret the information, summarizing key points, highlighting important sections, and surfacing items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Recent filings cover a dividend declaration and an insider stock sale.
CNMD PE Ratio & Valuation, Is CNMD Overvalued
This article analyzes Conmed Corp (CNMD) valuation, concluding it is currently undervalued. Based on its forward PE ratio of 27.17, CNMD is considered undervalued compared to its five-year average, with a fair price ranging from $35.14 to $57.45. The article also compares key metrics like P/B ratio, FCF yield, and P/S ratio against historical averages and competitors.
Analysis of Key Market Segments Driving the Gastrointestinal Devices Market
The gastrointestinal devices market is projected to reach $17.46 billion by 2030, growing at an 8.3% CAGR, driven by technological advancements like AI-assisted diagnostics and expanding endoscopy solutions. Key trends include increased adoption of advanced GI endoscopic techniques, capsule endoscopy systems, and minimally invasive treatments. Major players such as Olympus Corporation and Fujifilm Holdings Corporation are focusing on innovation and strategic acquisitions to enhance their market presence and product portfolios.
Trends in Growth, Segment Analysis, and Competitive Approaches
The hand-held surgical instruments market is projected to reach $12.96 billion by 2030, growing at an 11.5% CAGR, driven by advanced surgical techniques, infection prevention, and outpatient surgeries. Key players include Johnson & Johnson, B. Braun Melsungen AG, and Zimmer Biomet Holdings Inc., with significant innovation seen in precision tools and ergonomic designs. Recent acquisitions, such as STERIS PLC's purchase of Becton, Dickinson and Company's surgical assets, are shaping the competitive landscape.
CONMED Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
CONMED Corp., a small-cap pharmaceutical company, has experienced a significant downturn in its stock performance, returning -42.22% over the past year. Technical indicators suggest a bearish sentiment, and the stock has lagged considerably behind the S&P 500 over multiple time frames, including a -65.77% return over three years. This evaluation revision highlights the ongoing challenges faced by CONMED in the current market.
Responsive Playbooks and the CNMD Inflection
This article provides an in-depth analysis of Conmed Corp. (NASDAQ: CNMD) with a near-term neutral sentiment and a mid-channel oscillation pattern. It highlights an exceptional 46.6:1 risk-reward setup, targeting a 13.8% gain against 0.3% risk. The piece also details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis generated by AI models.
[SCHEDULE 13G/A] CONMED Corp Amended Passive Investment Disclosure
The Vanguard Group filed an amended Schedule 13G/A for CONMED Corp, reporting zero beneficial ownership of common stock as of March 13, 2026, signed on March 26, 2026. This change is due to an internal realignment on January 12, 2026, causing Vanguard's subsidiaries and business divisions to report beneficial ownership separately. The filing confirms 0% ownership and 0 shares by The Vanguard Group.
CONMED Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
CONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen a significant decline in its stock performance over the past year, returning -38.58% compared to the S&P 500's 16.12% gain. The stock is currently priced at $36.63, showing mixed technical signals with bearish sentiment in weekly indicators and a mix for monthly indicators, suggesting potential volatility. The company faces ongoing challenges in a competitive market, despite a recent slight increase from its previous close.
Is It Time To Reassess CONMED (CNMD) After A 39% One Year Share Price Slide
CONMED (CNMD) has seen its share price drop by 39% over the past year, leading investors to question its true value, despite holding a valuation score of 6/6. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 59.4%, with an intrinsic value of $88.46 compared to its current price of $35.94. Additionally, its P/E ratio of 23.6x is below the industry average and its calculated "Fair Ratio" of 26.4x, further indicating a potential discount on an earnings basis.
Tudor Investment Corp ET AL Acquires 83,418 Shares of CONMED Corporation $CNMD
Tudor Investment Corp ET AL significantly increased its stake in CONMED Corporation (NYSE:CNMD) by 200.9%, purchasing 83,418 additional shares and bringing its total holdings to 124,944 shares valued at approximately $5.88 million. Despite this large acquisition, analyst sentiment for CONMED has softened, with a consensus "Reduce" rating and an average price target of $50.17. The company recently exceeded quarterly earnings and revenue estimates.
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE)
Healthcare sector analysts have provided updates on several companies, including Conmed (CNMD), Alto Neuroscience, Inc. (ANRO), and Pfizer (PFE). Conmed received a Hold rating from Wells Fargo, while Alto Neuroscience, Inc. was reiterated with a Buy rating by H.C. Wainwright. Pfizer maintained a Hold rating from Wells Fargo.
CONMED (NYSE: CNMD) EVP granted 17,198 RSUs after award correction
CONMED's Executive VP RA, QA Brent Lalomia was granted 17,198 restricted stock units (RSUs) as a corrected award under the company's 2025 Long-Term Incentive Plan. This amended Form 4 filing clarifies that an initial grant of 9,554 RSUs was supplemented by a special award of 7,644 additional RSUs, bringing the total to 17,198 units. The RSUs will vest over a three-year period, with 33% vesting after one year, 33% after two years, and 34% after three years.
CONMED (NYSE: CNMD) VP granted 17,471 RSUs under 2025 incentive plan
CONMED Corporation's VP GM Advanced Surgical, Matthew Schabacker, was granted a corrected total of 17,471 Restricted Stock Units (RSUs) under the company's 2025 Long-Term Incentive Plan. This amendment to a Form 4/A filing clarifies that the total includes a special award of 7,644 RSUs in addition to the originally reported 9,827. The RSUs will generally vest over a three-year period.
Executive VP at CONMED (CNMD) awarded 16,926 RSUs in corrected Form 4/A
John D. Ferrell, Executive Vice President – HR at CONMED Corporation (CNMD), was awarded 16,926 restricted stock units (RSUs) as compensation. This updated amount was disclosed in an amended Form 4/A filing, correcting the initial report by adding a special award of 7,644 RSUs to the previously stated 9,282 RSUs. The RSUs are part of the company's 2025 Long-Term Incentive Plan and will vest over a three-year period.
CONMED (CNMD) grants 18,563 RSUs to its general counsel Foust
CONMED Corporation's General Counsel and Corporate Secretary, Hollie K. Foust, was granted 18,563 restricted stock units (RSUs) under the company's 2025 Long-Term Incentive Plan. This grant, which vests over three years, was detailed in an amended Form 4/A filing to correct the initial reported amount. The total RSU grant includes a special award of 7,644 RSUs in addition to the originally reported 10,919 RSUs.
Micro-Tech Endoscopy Signs Definitive Agreement to Acquire Duraclip™, Precisor®, and Optibite® Product Lines from CONMED
Micro-Tech Endoscopy has signed a definitive agreement to acquire the global distribution rights for the Duraclip™, Precisor®, and Optibite® product lines from CONMED Corporation. This acquisition strengthens Micro-Tech's GI endoscopy portfolio and ensures continued access to these products for clinicians, particularly as CONMED exits the gastroenterology market. Micro-Tech, which has been the original manufacturer of these devices, will integrate them into its U.S. and global commercial operations.
Understanding the Setup: (CNMD) and Scalable Risk
This article analyzes Conmed Corp. (NASDAQ: CNMD), highlighting weak sentiment across all horizons and an exceptional 44.0:1 risk-reward short setup. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis. The report suggests a short bias due to weak sentiment and provides specific entry, target, and stop-loss zones.
Here's why you should retain CONMED stock in your portfolio now
The provided article content is empty. Therefore, a summary cannot be generated.
CONMED (NYSE: CNMD) appoints Andrew Moller interim principal financial officer
CONMED Corporation (NYSE: CNMD) has appointed Andrew Moller, 51, as Interim Principal Financial Officer, effective March 15, 2026. Moller currently serves as Vice President, Corporate Controller and Principal Accounting Officer, a position he has held since April 2025. His compensation arrangements remain unchanged with this interim appointment, and there are no related-party transactions or family relationships with the company's directors.
CONMED Corp. Experiences Valuation Adjustment Amidst Competitive Market Dynamics
CONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, with its stock price declining and a negative stock return over the past year. Despite a fair valuation, its metrics show a mixed landscape compared to peers like Globus Medical and Sanmina, highlighting the competitive challenges within the industry. The company's current price is $39.90, down from $41.40, with a P/E ratio of 18 and a dividend yield of 155.87%.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED Corporation (CNMD) is positioned for growth due to the increasing adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, along with rising robotic procedure volumes and improving supply chains. Despite tariff headwinds and increased operating expenses impacting near-term EPS, the company's long-term prospects are bolstered by strategic investments, margin improvement initiatives, and a $150 million share repurchase program. However, competition and a declining estimate revision trend for fiscal 2026 remain concerns.
CONMED Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape
CONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has undergone a valuation adjustment with a P/E ratio of 18 and a high dividend yield of 155.87%. The company's financial metrics include a Price to Book Value of 1.57, EV to EBIT of 16.64, EV to EBITDA of 11.96, ROCE of 7.88%, and ROE of 8.88%. This adjustment reflects its position within a competitive market, where it demonstrates a lower P/E ratio compared to some competitors while facing others rated more favorably.
CONMED (NYSE: CNMD) EVP granted RSUs and stock options in 2026 award
CONMED Corp's Executive Vice President, Brent Lalomia, was granted 9,554 restricted stock units (RSUs) and 11,322 stock options on March 2, 2026. These awards are part of the company's 2025 Long-Term Incentive Plan, aiming to align his compensation with CONMED's long-term performance. The RSUs vest over three years, while the stock options vest in equal installments over four years.
The Technical Signals Behind (CNMD) That Institutions Follow
This article provides a technical analysis of Conmed Corp. (NASDAQ: CNMD) for institutional investors, highlighting potential weaknesses in near-term sentiment within a broader long-term weak bias. It outlines distinct trading strategies (Position, Momentum Breakout, Risk Hedging) based on AI models, offering specific entry, target, and stop-loss points. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
CONMED (CNMD) HR executive awarded RSUs and stock options under 2025 plan
CONMED Corp's Executive Vice President of HR, John D. Ferrell, was granted 9,282 Restricted Stock Units (RSUs) and options to purchase 10,999 shares of common stock under the company's 2025 Long-Term Incentive Plan. The RSUs vest over three years, while the stock options vest in equal installments over four years. This comes from a Form 4 SEC filing detailing insider trading activity.
CNMD Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive overview of Conmed Corp's (CNMD) financial statements, including income statements, balance sheets, and cash flow data, updated for fiscal year 2025. It details key financial metrics, growth rates, profitability, and liquidity scores, and includes an analysis of the company's financial health indicators like the Altman Z-Score and Piotroski F-Score. The report indicates a moderate overall financial health for Conmed Corp.
Director Mark Kaye converts 152 RSUs at CONMED (NYSE: CNMD) into stock
CONMED director Mark Kaye has converted 152 Restricted Stock Units (RSUs) into common stock on February 24, 2026, as reported in a Form 4 SEC filing. This transaction, which is part of CONMED’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, resulted in Kaye directly holding 152 shares of CONMED common stock. The RSUs generally vest 100% after one year, with accelerated vesting upon termination of the director's service.
3 Reasons CNMD is Risky and 1 Stock to Buy Instead
The article identifies CONMED (CNMD) as a risky stock due to its lackluster revenue growth, limited distribution channels affecting its scale in a regulated industry, and negative revenue projections from Wall Street analysts. Despite a seemingly fair valuation, the author suggests the stock lacks significant upside. Instead, the article recommends exploring other high-quality stocks in the market, highlighting StockStory's curated lists for potential market-beating returns.
CONMED Corp SEC 10-K Report
CONMED Corporation has released its 2025 Form 10-K report, revealing a 5.2% increase in net sales to $1,374.7 million but a significant decrease in net income to $47.1 million due to higher operating expenses and tax rates. The company is focusing on strategic initiatives such as product portfolio optimization, a share repurchase program, and exploring acquisitions, while navigating challenges like regulatory compliance, supply chain disruptions, and competitive market pressures.
A Look At CONMED (CNMD) Valuation After Earnings And Growth In Key Surgical Segments
CONMED (CNMD) shares are gaining attention after reporting strong Q4 and full-year 2025 results, issuing positive 2026 revenue guidance, and showcasing momentum in key surgical segments. Despite a recent dip in its stock price over the last year, the company is trading at a significant discount to its estimated fair value, suggesting a potential undervaluation at US$39.93 against a fair value of US$48.40. Investors are now evaluating whether this indicates a mispriced opportunity or if market concerns about supply chain issues and hospital budget pressures overshadow its long-term growth prospects, particularly in minimally invasive and robotic-assisted surgeries.
5 Must-Read Analyst Questions From CONMED's Q4 Earnings Call
CONMED (CNMD) reported strong Q4 results, exceeding revenue and adjusted EPS estimates, largely driven by its orthopedics portfolio and resolving supply chain issues. The company is strategically shifting focus to high-growth areas like robotic surgery and orthopedics while exiting lower-growth product lines. Analyst questions focused on revenue seasonality, organic growth figures, drivers of orthopedic outperformance, international demand, and future M&A strategy.
Conmed Corporation stock hits 52-week low at 38.05 USD
Conmed Corporation's stock has hit a 52-week low at $38.05, reflecting a significant decline over the past year with a 1-year total return of -44.43%. Despite the stock's underperformance, InvestingPro analysis indicates that the company maintains strong fundamentals, including a current ratio of 2.1, and is projected to be profitable this fiscal year. This comes after the medical technology firm reported stronger-than-expected earnings and revenue for Q4 2025, with an adjusted EPS of $1.43 and revenue of $373.2 million.
CONMED Corporation (NYSE:CNMD) Q4 2025 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD) reported a strong Q4 and full-year 2025, with total sales increasing 7.9% and 5.2% respectively. The company beat earnings expectations with an adjusted EPS of $1.43 against an expected $1.32. CONMED is narrowing its focus to high-growth, high-margin markets, exiting gastroenterology product lines, and making significant progress in its orthopedic supply chain and key growth platforms like AirSeal, Buffalo Filter, and BioBrace, while also announcing a CFO transition.
CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
CONMED (NYSE:CNMD) reported better-than-expected Q4 CY2025 revenue, up 7.9% year-on-year, driven by strong orthopedics performance and resolved supply chain issues. The company is strategically refocusing on high-growth areas like robotic surgery and exiting lower-growth gastroenterology products, which is projected to improve long-term gross margins despite anticipated headwinds from tariffs. Management's outlook for 2026 reflects confidence in core growth drivers and increased R&D investment, while also acknowledging potential impacts from tariffs and portfolio adjustments on EPS.
CONMED Corp shares slip after Q4 earnings beat, cautious guidance
CONMED Corp (NYSE: CNMD) shares dipped after reporting Q4 2025 earnings that beat expectations but were accompanied by cautious guidance for 2026. Despite moderate growth in Q4 sales and full-year revenue, and an increase in adjusted diluted EPS, the company's stock fell due to the conservative outlook and plans to exit its gastroenterology portfolio to focus on core markets. This has contributed to a recent downtrend and significant volatility in its share price.
Conmed: Fourth Quarter Financial Highlights
Conmed Corp. reported strong financial results for its fourth quarter, with a net profit of $16.7 million and adjusted earnings of $1.43 per share, surpassing analyst expectations. The medical technology firm generated $373.2 million in revenue and provided optimistic annual earnings and revenue projections for the coming year.
(CNMD) CONMED Expects 2026 Revenue Range $1.35B-$1.38B, vs. FactSet Est of $1.38B
CONMED Corporation (CNMD) has provided its preliminary outlook for fiscal year 2026, anticipating total reported revenue to be in the range of $1.35 billion to $1.38 billion. This forecast is slightly below the FactSet estimate of $1.38 billion. The announcement was made following the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference.
CONMED (NYSE:CNMD) Beats Q4 CY2025 Sales Expectations, Stock Soars
CONMED (NYSE:CNMD) reported Q4 CY2025 results that exceeded revenue expectations, with sales up 7.9% year-on-year to $373.2 million and non-GAAP EPS of $1.43, beating analyst estimates by 8%. However, the company's full-year revenue guidance for 2026 slightly missed analysts' estimates, and its operating margin decreased by 5.4 percentage points year-on-year in Q4. Despite mixed results, the stock traded up 5.4% immediately following the announcement, indicating a positive market reception to the revenue beat.
Conmed: Q4 Earnings Snapshot
Conmed Corp. (CNMD) reported strong fourth-quarter earnings, beating Wall Street expectations with $1.43 per share adjusted, compared to an average estimate of $1.32 per share. The medical technology company posted $373.2 million in revenue for the quarter. For the full year, Conmed reported a profit of $47.1 million, or $1.51 per share, on revenue of $1.37 billion, and provided optimistic guidance for the upcoming year.
Earnings Flash (CNMD) CONMED Corporation Reports Q4 Revenue $373.2M, vs. FactSet Est of $366.9M
CONMED Corporation (CNMD) reported its Q4 revenue of $373.2 million, surpassing FactSet's estimate of $366.9 million. The company, a medical technology firm, specializes in surgical devices and equipment for minimally invasive procedures across various medical specialties. This announcement comes amid other recent news including CFO transition and reaffirmation of consolidated earnings guidance for the full year 2025.
(CNMD) CONMED Expects 2026 Adjusted Earnings Range $4.30-$4.45, vs. FactSet Est of $4.50
CONMED (CNMD) has announced its adjusted earnings expectations for 2026, forecasting a range of $4.30 to $4.45 per share. This projection falls below the FactSet estimate of $4.50 per share. The medical technology company's guidance was released on January 28, 2026, alongside its Q4 2025 earnings report.
Conmed: Fourth Quarter Financial Highlights
Conmed Corp. reported strong financial results for the fourth quarter, with a net profit of $16.7 million and adjusted earnings of $1.43 per share, surpassing analyst expectations. The medical technology firm generated $373.2 million in revenue and provided optimistic annual earnings and revenue projections for the future.
CONMED Corporation (CNMD): Stock Analysis Reveals 18% Potential Upside Amidst Healthcare Sector Dynamics
CONMED Corporation (CNMD), a medical device company, is highlighted for its specialized focus on surgical equipment, despite current valuation challenges. The stock holds an 18% potential upside according to analysts, driven by its robust free cash flow, strategic product portfolio, and solid dividend yield. Technical indicators suggest the stock is nearing oversold territory, making it a potential buying opportunity for investors in the medical technology space.
Conmed: Q4 Earnings Snapshot
Conmed Corp. (CNMD) reported strong fourth-quarter earnings, surpassing Wall Street expectations with adjusted earnings of $1.43 per share on revenue of $373.2 million. For the full year, the company posted a profit of $47.1 million and revenue of $1.37 billion. Conmed also provided optimistic full-year guidance, projecting earnings between $4.30 and $4.45 per share and revenue in the range of $1.35 billion to $1.38 billion.
CONMED Earnings: What To Look For From CNMD
CONMED (NYSE:CNMD) is set to announce its earnings results this Wednesday. Analysts expect revenue to grow 6.1% year-on-year to $367 million with adjusted earnings of $1.32 per share. The company has a history of missing Wall Street's revenue estimates and is currently trading below the average analyst price target.
Mountain Pacific Investment Advisers LLC Sells 112,031 Shares of CONMED Corporation $CNMD
Mountain Pacific Investment Advisers LLC significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by selling 112,031 shares, cutting its holdings by 80.1%. This move aligns with a broader negative sentiment from Wall Street analysts, who have issued "Reduce" ratings and lowered price targets for CONMED. Despite this, CONMED slightly surpassed its Q3 EPS estimates and provided positive FY2025 earnings guidance.
Conmed's chief information officer sells $16,796 in common stock
Conmed's Chief Information Officer recently sold 188 shares of the company's common stock, totaling approximately $16,796. This transaction occurred at a price of $89.34 per share. Following this sale, the officer still directly owns 7,994 shares of Conmed stock.
Surgical Equipment & Consumables - Diversified Stocks Q3 Results: Benchmarking CONMED (NYSE:CNMD)
This article analyzes the Q3 earnings results for the surgical equipment and consumables - diversified industry, focusing on CONMED (NYSE:CNMD) and its peers. It highlights CONMED's satisfactory quarter with revenues up 6.7% year-on-year, while also benchmarking it against best performer STERIS (NYSE:STE) and weakest performer BD (NYSE:BDX), along with Solventum (NYSE:SOLV) and Zimmer Biomet (NYSE:ZBH). The industry faces tailwinds from aging populations and integrating AI/robotics, but also headwinds like supply chain issues and regulatory changes.
SG Americas Securities LLC Acquires 61,860 Shares of CONMED Corporation $CNMD
SG Americas Securities LLC significantly increased its stake in CONMED Corporation (NYSE:CNMD) by 3,041.3%, acquiring 61,860 additional shares to hold a total of 63,894 shares valued at approximately $3.01 million. This comes amidst a negative shift in analyst sentiment, leading to multiple price target cuts and a "Reduce" consensus rating for CONMED. Despite this, CONMED recently surpassed quarterly EPS expectations and provided FY2025 guidance.
